PARP Inhibitors in Prostate Cancer – Recent Updates and Implications for Clinical Practice

October 29, 2023

This CME-accredited activity, PARP Inhibitors in Prostate Cancer – Recent Updates and Implications for Clinical Practice, is designed to provide expert interpretation of new and emerging data on the treatment of prostate cancer with PARP inhibitors (PARPi) as a single agent or potential new combination treatments. Expert faculty will discuss the essentials of clinical trial data and current and emerging treatment strategies and place them within a practical and contemporary clinical context for developing and maintaining updated care pathways for patients with advanced prostate cancer. The goal of this activity is to improve knowledge and advance the ability of oncology providers to apply current and emerging treatment strategies with PARPi to the clinical Practice in improving outcomes of patients with prostate cancer.

Target Audience

  • Cancer care professionals
  • Practicing medical oncologists/hematologists
  • Medical oncology and hematology fellows
  • Oncology nurses
  • Nurse practitioners
  • Physician assistants
  • Pharmacists

 

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Review the science, mechanism of action, and clinical rationale for PARP-inhibitors and PARP-inhibitor/androgen receptor combinations to treat patients with advanced prostate cancer
  • Summarize current clinical trial data and clinical applications for new and emerging therapies, including PARP inhibitors combined with androgen receptor-targeted therapies 
  • Review the evolving paradigm of potential treatment strategies and patient adherence factors for PARP inhibitor combinations to improve outcomes in patients with advanced prostate cancer
  • Identify and manage treatment-related toxicities based on recent clinical trials data on PARP inhibitors
  • Review the role of germline and somatic mutation testing and identification of biomarkers that predict PARP inhibitor sensitivity
Course summary
Available credit: 
  • 2.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 2.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 2.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 2.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 2.00 Contact Hours.
Course opens: 
08/25/2023
Course expires: 
12/29/2023
Event starts: 
10/29/2023 - 8:00am PDT
Event ends: 
10/29/2023 - 10:00am PDT
Cost:
$0.00
Add to calendar: 

OCTOBER 29, 2023

All times are listed in Pacific Daylight Time (PDT)

07:30 AM - 08:00 AM: Networking

08:00 AM – 08:20 AM: Rationale for PARPi in the management of prostate cancer - Alexandra Sokolova, MD

08:20 AM – 08:40 AM: Combination of PARP-I + ARSI and other PARPi combinations - Benjamin Garmezy, MD

08:40 AM - 09:00 AM: PARPi in metastatic hormone sensitive prostate cancer and earlier disease settings - Karine Tawagi, MD

09:00 AM – 09:20 AM: Germline and somatic mutation testing and identifying predictive biomarkers for PARPi - Natalie Reizine, MD

09:20 AM – 09:40 AM: Toxicities management of regimens including PARPi - Jason Brown, MD, PhD

09:40 AM – 10:00 AM: Panel discussion -  Benjamin Garmezy, MD,  Karine Tawagi, MD, Natalie Reizine, MD, and Jason Brown, MD, PhD

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

 

Course Director(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Speaker/Topic Presenter(s)

Jason Brown

has a financial relationship (Other) with AstraZeneca;.
has a financial relationship (Other) with EMD Serono;.

Benjamin Garmezy, MD

has a financial relationship (Other) with Zenshine;.
has a financial relationship (Other) with Merck;.
has a financial relationship (Other) with Accutar;.
has a financial relationship (Other) with CRISPR Therapeutics;.
has a financial relationship (Other) with IDEAYA Biosciences;.
has a financial relationship (Other) with Kineta;.
has a financial relationship (Other) with Nuvation Bio;.
has a financial relationship (Other) with Xencor;.
has a financial relationship (Other) with Bayer;.
has a financial relationship (Other) with SeaGen;.
has a financial relationship (Other) with Abbvie;.
has a financial relationship (Other) with AVEO;.
has a financial relationship (Other) with Harbour BioMed;.
has a financial relationship (Other) with Jubilant Therapeutics;.
has a financial relationship (Other) with Mink Therapeutics;.
has a financial relationship (Other) with TEON Therapeutics;.
has a financial relationship (Other) with Arvinas;.
has a financial relationship (Other) with Sanofi-Aventis;.
has a financial relationship (Other) with AstraZeneca;.
has a financial relationship (Other) with Genetech/Roche;.
has a financial relationship (Other) with Janux Therapeutics;.
has a financial relationship (Other) with Loxo;.
has a financial relationship (Other) with Amgen ;.
has a financial relationship (Other) with Pfizer;.
has a financial relationship (Other) with Arcus;.
has a financial relationship (Other) with Exelixis;.
has a financial relationship (Other) with Janssen;.
has a financial relationship (Other) with Kinnate Biopharma;.
has a financial relationship (Other) with Profound Bio;.

Natalie Reizine, MD

has a financial relationship (Financial Support) with EMD Serono;.
has a financial relationship (Financial Support) with Sanofi;.
has a financial relationship (Financial Support) with Tempus;.
has a financial relationship (Financial Support) with AstraZeneca;.
has a financial relationship (Financial Support) with Janssen;.
has a financial relationship (Financial Support) with Merck;.
has a financial relationship (Financial Support) with Exelexis;.

Alexandra Sokolova

has a financial relationship (Professional Services) with Lantheus;.
has a financial relationship (Travel) with Asta Zeneca;.

Karine Tawagi, MD

has no relevant financial relationships to disclose at this time.

COMMERCIAL SUPPORT ACKNOWLEDGMENT

This activity is supported with an independent medical education grant from the following companies:

  • Merck Sharp & Dohme LLC
  • AstraZeneca Pharmaceuticals

Available Credit

  • 2.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 2.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 2.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 2.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 2.00 Contact Hours.

 

 

Price

Cost:
$0.00
Please login or register to take this course.

This webinar is free for health care providers.
If you are employed by the industry, you must register as "Industry representative" even if you are a licensed healthcare provider not involved in the sales of product. The industry price is applicable to everyone who are employed by an ACCME defined ineligible company. The industry price is $250.
An ineligible company is any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients with the exception of hospitals and facilities that provide direct care to patients.

CANCELLATION POLICY
You may cancel your enrollment at any time.
No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity, and completion of pre & post tests as well as course evaluations.